Kurser indlæses...
Prognose
Analytikernes gennemsnitlige kursmål er 4,47 € (+241,22 %). Medianen er 4,47 € (+241,22 %).
| Køb |
2 |
| Behold |
0 |
| Sælg |
0 |
Nyheder Til nyhedsfeedet
Insider purchase at OKYO Pharma: CSO Raj Patil increases holdings
Raj Patil, chief scientific officer of OKYO Pharma, bought 3,363 common shares on the NASDAQ at $1.49 each, bringing his holdings to 20,030 shares. OKYO Pharma is preparing to start a global phase‑3 trial in the second half of the year with about 111 patients to evaluate a single dose of urcosimod for neuropathic corneal pain. » Mere på de.investing.com
OKYO Pharma: CEO Robert J. Dempsey buys 15,000 shares at $1.54
Chief Executive Officer Robert J. Dempsey purchased 15,000 common shares of OKYO Pharma on the open market at $1.54 per share on the NASDAQ. OKYO Pharma is listed on the Nasdaq Capital Market and plans to start a global phase‑3 single‑dose study of urcosimod for neuropathic corneal pain in the second half of the year with about 111 patients. The company is in the clinical development phase for anterior segment eye therapies. » Mere på de.investing.com
OKYO Pharma: chief development officer Gary S. Jacob buys 3,500 shares
Gary S. Jacob, chief development officer and director of OKYO Pharma, purchased 3,500 common shares at $1.40 each on the Nasdaq, bringing his total holding to 112,420 shares. OKYO Pharma’s common stock is listed on the Nasdaq Capital Market. The biopharmaceutical company plans to start a global, registration‑enabling Phase 3 study of urcosimod for the treatment of neuropathic corneal pain in the second half of the year, likely with around 111 patients and a single‑dose regimen. » Mere på de.investing.com
Virksomhedstal
| (EUR) | marts 2026 | YoY |
|---|---|---|
| Omsætning | 0 | - |
| Bruttofortjeneste | -807,75 | - |
| Nettoresultat | -5,5 mio. | - |
| EBITDA | -5,53 mio. | - |
Fundamentale data
| Nøgletal | Værdi |
|---|---|
Markedsværdi | 68,95 mio. € |
Antal aktier | 52,48 mio. |
Højeste/laveste i 52 uger | 2,86 € - 1,13 € |
| Udbytte | Nej |
Beta | 0,05 |
P/E (PE Ratio) | -6,15 |
PEG (PEG Ratio) | 0,05 |
K/I (PB Ratio) | 4,46 |
P/S (PS Ratio) | 0,00 |
Virksomhedsprofil
OKYO Pharma Limited er et prækliniskt biofarmaceutisk selskab, der udvikler terapeutika til patienter med inflammatoriske øjensygdomme og okulær smerte i Storbritannien. Selskabets førende produkt er OK-101 til behandling af tør øjesygdom. Selskabet udvikler desuden OK-201, en bovin binyremarv-baseret, lipideret peptid-præklinisk analogkandidat til behandling af neuropatisk okulær smerte. OKYO Pharma Limited blev stiftet i 2007 og har hovedkontor i London, Storbritannien.
| Navn | OKYO PHARMA LTD Aktie |
| CEO | Robert J. Dempsey |
| Hjemsted | London,
gl Storbritannien |
| Websted | |
| Branche | Fødevarer |
| Børsnotering | 17.05.2022 |
| Medarbejdere | 5 |
Deep Dive
Tickersymboler
| Børs | Symbol |
|---|---|
NASDAQ | OKYO |
Frankfurt | OK11.F |
München | OK11.MU |
